Actively Recruiting
Efficacy and Safety of Fecal Microbiota Transplantation
Led by Guangzhou First People's Hospital · Updated on 2021-04-08
300
Participants Needed
1
Research Sites
310 weeks
Total Duration
On this page
AI-Summary
What this Trial Is About
In recent years, researches illustrate that multifactorial diseases such as functional gastrointestinal disorders, autoimmune diseases, metabolic, behavioral and neurological diseases are associated with an abnormal microbiome structure-dysbiosis, which means the imbalance of the microbiome community. Fecal microbiota transplantation (FMT), the infusion of faeces from a healthy donor to the gastrointestinal tract of a recipient patient aiming to alter the intestine microbiota, is recommended to be performed in Clostridium difficile infection(CDI) as the most effective therapy. It also being used experimentally in the treatment of the disease states linked to dysbiosis of the intestinal microbiota. However, the efficacy and safety of FMT to treat the dysbiosis-associated diseases is still in its infancy. To further verify the indications above, more data is required to be collected through studies.
CONDITIONS
Official Title
Efficacy and Safety of Fecal Microbiota Transplantation
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Confirmed diagnosis of one or more of the following diseases: Irritable Bowel Syndrome, Ulcerative colitis, Crohn's disease, Constipation, Clostridium Difficile Infection, Functional Dyspepsia, Parkinson's Disease, Metabolic Syndrome, Non-Alcoholic Fatty Liver Disease, Autism Spectrum Disorder, Radiation Enteritis, Atopic Dermatitis, Food Allergy, Graft-versus-Host Disease, Obesity, Diabetes mellitus, Multi-Drug Resistant Infection, Hepatic Encephalopathy, Enteric Dysbacteriosis, Multiple Sclerosis, Pseudomembranous Enteritis, Acute Pancreatitis, Chronic Fatigue Syndrome, Acute-on-chronic Liver Failure with HBV Infection, Alcoholic Liver Disease, Anorexia, Decompensated Cirrhosis, Henoch-Schonlein Purpura, Autoimmune Liver Disease, Systemic Lupus Erythematosus, Rheumatoid arthritis, IgG4-Related Disease, Celiac Disease, Protein-losing Enteropathy, Asperger Syndrome, Psoriasis, Ankylosing spondylitis, Immune checkpoint inhibition-related colitis, Autoimmune enteropathy, Drug-induced diarrhea
- Suffering from gastrointestinal symptoms such as constipation, diarrheas, abdominal pain, flatulence, etc.
- Able to tolerate FMT infusion methods such as endoscopy, colonoscopy, capsule, nasoduodenal tube insertion, etc.
You will not qualify if you...
- Currently pregnant or breastfeeding
- Suffering from other severe diseases including liver or kidney failure, heart failure, multiple organ dysfunction syndrome (MODS), coma, or cerebrovascular accident
- Known contraindications to all FMT infusion methods such as nasoduodenal tube insertion, endoscopy, colonoscopy, and enema
- Any conditions that may reduce the efficacy of FMT or as determined by the investigators
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 1 location
1
Guangzhou First People's Hospital
Guangzhou, Guangdong, China, 510180
Actively Recruiting
Research Team
Y
Yongjian Zhou, MM
CONTACT
H
Hongli Huang, MM
CONTACT
How is the study designed?
Study Type
INTERVENTIONAL
Masking
NONE
Allocation
NON_RANDOMIZED
Model
PARALLEL
Primary Purpose
TREATMENT
Number of Arms
40
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here